- Long term Safety Follow up of Subject With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004
- A Phase 2 Study of Erdafitinib in Subjects with Advanced Solid Tumors and FGFR Gene Alterations.
- A Phase 4, Open- Tolerability of a Three-day Fosaprepitant Regimen Administered for the Prevention of Chemotherapy- Induced Nausea and Vomiting (CINV) in Pediatric Induced Nausea and Vomiting (CINV) in Pediatric Participants Receiving Emetogenic Chemotherapy.“ protocol No. 045.
- Noncommercial Clinical Trail: Ewing 2008, EudraCT number: 2008-003658-13, Trial Code: Ewing 2008.
- Noncommercial Clinical Trail: “LCH-IV” EudraCT number: 2011-001699-20
- Trial for Localised High-risk Rhabdomyosarcoma and Rhabdomyosarcoma-like Soft Tissue Sarcoma (CWS-2007-HR).
- The POL HISTIO project is a non-commercial clinical trial aimed at optimizing the diagnosis and treatment of juvenile patients with histiocytosis. The project is intended to include patients from all over Poland. The project is funded by the Medical Research Agency.
-Determination of molecular status, as well as the efficacy and safety of fluorodeoxyglucose (18F-FDG) in PET-CT imaging in juvenile patients with histiocytosis.
-Optimization of the time and dosage of vemurafenib in BRAF positive juvenile patients with refractory histiocytosis.
-Optimization of the time and dosage of trametinib in BRAF negative juvenile patients with refractory histiocytosis or after the failure of vemurafenib treatment.